Latinović, Nataša

Link to this page

Authority KeyName Variants
60fee721-f356-4a2b-b7e8-e279be8f8387
  • Latinović, Nataša (1)
Projects

Author's Bibliography

Nanoformulations of doxorubicin: How far have we come and where do we go from here?

Borišev, Ivana; Mrđanović, Jasminka Ž.; Petrović, Danijela; Seke, Mariana; Jović, Danica S.; Srđenović, Branislava U.; Latinović, Nataša; Đorđević, Aleksandar N.

(2018)

TY  - JOUR
AU  - Borišev, Ivana
AU  - Mrđanović, Jasminka Ž.
AU  - Petrović, Danijela
AU  - Seke, Mariana
AU  - Jović, Danica S.
AU  - Srđenović, Branislava U.
AU  - Latinović, Nataša
AU  - Đorđević, Aleksandar N.
PY  - 2018
UR  - http://stacks.iop.org/0957-4484/29/i=33/a=332002?key=crossref.4804877570e2609bf6333877ee495ab3
UR  - http://vinar.vin.bg.ac.rs/handle/123456789/7751
AB  - Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior.
T2  - Nanotechnology
T1  - Nanoformulations of doxorubicin: How far have we come and where do we go from here?
VL  - 29
IS  - 33
SP  - 332002
DO  - 10.1088/1361-6528/aac7dd
ER  - 
@article{
author = "Borišev, Ivana and Mrđanović, Jasminka Ž. and Petrović, Danijela and Seke, Mariana and Jović, Danica S. and Srđenović, Branislava U. and Latinović, Nataša and Đorđević, Aleksandar N.",
year = "2018",
abstract = "Nanotechnology, focused on discovery and development of new pharmaceutical products is known as nanopharmacology, and one research area this branch is engaged in are nanopharmaceuticals. The importance of being nano has been particularly emphasized in scientific areas dealing with nanomedicine and nanopharmaceuticals. Nanopharmaceuticals, their routes of administration, obstacles and solutions concerning their improved application and enhanced efficacy have been briefly yet comprehensively described. Cancer is one of the leading causes of death worldwide and evergrowing number of scientific research on the topic only confirms that the needs have not been completed yet and that there is a wide platform for improvement. This is undoubtedly true for nanoformulations of an anticancer drug doxorubicin, where various nanocarrriers were given an important role to reduce the drug toxicity, while the efficacy of the drug was supposed to be retained or preferably enhanced. Therefore, we present an interdisciplinary comprehensive overview of interdisciplinary nature on nanopharmaceuticals based on doxorubicin and its nanoformulations with valuable information concerning trends, obstacles and prospective of nanopharmaceuticals development, mode of activity of sole drug doxorubicin and its nanoformulations based on different nanocarriers, their brief descriptions of biological activity through assessing in vitro and in vivo behavior.",
journal = "Nanotechnology",
title = "Nanoformulations of doxorubicin: How far have we come and where do we go from here?",
volume = "29",
number = "33",
pages = "332002",
doi = "10.1088/1361-6528/aac7dd"
}
Borišev, I., Mrđanović, J. Ž., Petrović, D., Seke, M., Jović, D. S., Srđenović, B. U., Latinović, N.,& Đorđević, A. N.. (2018). Nanoformulations of doxorubicin: How far have we come and where do we go from here?. in Nanotechnology, 29(33), 332002.
https://doi.org/10.1088/1361-6528/aac7dd
Borišev I, Mrđanović JŽ, Petrović D, Seke M, Jović DS, Srđenović BU, Latinović N, Đorđević AN. Nanoformulations of doxorubicin: How far have we come and where do we go from here?. in Nanotechnology. 2018;29(33):332002.
doi:10.1088/1361-6528/aac7dd .
Borišev, Ivana, Mrđanović, Jasminka Ž., Petrović, Danijela, Seke, Mariana, Jović, Danica S., Srđenović, Branislava U., Latinović, Nataša, Đorđević, Aleksandar N., "Nanoformulations of doxorubicin: How far have we come and where do we go from here?" in Nanotechnology, 29, no. 33 (2018):332002,
https://doi.org/10.1088/1361-6528/aac7dd . .
16
15
15